This application requests funding for a CCSG grant for the University of Colorado Cancer Center (UCCC) for years 09-13. The University of Colorado Cancer Center is a """"""""Center"""""""" within the School of medicine at the University of Colorado Health Sciences Center. The Cancer Center goals are; 1) to contribute through coordinated research, clinical, prevention and control and educational activities effort to the eventual elimination of cancer as a human health problem, and 2) to provide the citizens of the State of Colorado and the Rocky Mountains region with state of the art cancer research, therapy, prevention, control and educational programs. The Cancer Center serves more than 6 million people in Colorado and the 7 surrounding states in the Rocky Mountain region. The over 280 Cancer Center members have more than $48 million (annual direct costs) in peer- reviewed grants an contracts relating to the cancer problem. Cancer Center members provide care to 15-20% of the cancer population in the region and enter more than 1,600 patients on cancer clinical trials each year. The Cancer Center enters an increasing number of patients of clinical trials emphasizing novel trials of the Center and high priority trials of the National Cancer Institute. The majority of cancer educational, prevention and control programs in the region are organized by Cancer Center members. The Center provides the major centralized support for these functions through its 11 shared """"""""core"""""""" facilities in Biostatistics, Clinical Investigations, Cytogenetics, Fermentation, Flow Cytometry, Histopathology/Tissue Procurement, Laboratory Animals/Transgenic Animals, Macromolecular Resources, Radiological Sciences, Immunology and Tissue Culture/Monoclonal Antibodies. The Cancer Center has 14 institutional members including the Health Sciences Center schools, affiliated hospitals and other institutions with a primary focus in cancer. The chief executive officers of these organizations form the Cancer Center Board which assures coordination of the cancer effort in the region. The Cancer Center has four major program divisions: Basic Research, Clinical Activities, Education and prevention and Control and is developing a Community Research Division. The Basic Research Division is divided into: Immunology; Molecular Biology; Growth Regulation; Cell Surface; Hormones an Cancer; Chromosomes and Mutation. The Clinical Division is divided into: Adult Clinical Oncology, Breast Cancer, Lung Cancer and Pediatric oncology; and the Prevention and Control Division is divided into Causation and Clinical Prevention and Control programs. The UCCC is currently an NCI designated """"""""Clinical Cancer Center"""""""". Our plans are to seek approval as an """"""""NCI Comprehensive Cancer Center"""""""" during the next funding cycle.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-11
Application #
2667909
Study Section
Cancer Centers and Research Programs Review Committee (CCRP)
Program Officer
Bhorjee, Jaswant
Project Start
1988-03-01
Project End
2001-01-31
Budget Start
1998-03-01
Budget End
1999-01-31
Support Year
11
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Collins, Keagan P; Jackson, Kristen M; Gustafson, Daniel L (2018) Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation. J Pharmacol Exp Ther 365:447-459
Villalobos, Victor Manuel; Hall, Francis; Jimeno, Antonio et al. (2018) Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol 25:768-775
Montford, John R; Lehman, Allison M B; Bauer, Colin D et al. (2018) Bone marrow-derived cPLA2? contributes to renal fibrosis progression. J Lipid Res 59:380-390
Kogut, Igor; McCarthy, Sandra M; Pavlova, Maryna et al. (2018) High-efficiency RNA-based reprogramming of human primary fibroblasts. Nat Commun 9:745
Nellan, Anandani; Rota, Christopher; Majzner, Robbie et al. (2018) Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer 6:30
Goodspeed, Andrew; Jean, Annie; Costello, James C (2018) A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer. Eur Urol :
Niemeyer, Brian F; Oko, Lauren M; Medina, Eva M et al. (2018) Host Tumor Suppressor p18INK4c Functions as a Potent Cell-Intrinsic Inhibitor of Murine Gammaherpesvirus 68 Reactivation and Pathogenesis. J Virol 92:
Kiseljak-Vassiliades, Katja; Zhang, Yu; Bagby, Stacey M et al. (2018) Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer 25:437-451
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Abraham, Christopher G; Ludwig, Michael P; Andrysik, Zdenek et al. (2018) ?Np63? Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep 24:3224-3236

Showing the most recent 10 out of 1634 publications